Diabetic Nephropathy - -Pipeline Review, H1 2014





Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H1 2014’, provides an overview of the Diabetic Nephropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Nephropathy Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Nephropathy - Overview 10
Pipeline Products for Diabetic Nephropathy - Comparative Analysis 11
Diabetic Nephropathy - Therapeutics under Development by Companies 12
Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 16
Diabetic Nephropathy - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Diabetic Nephropathy - Products under Development by Companies 21
Diabetic Nephropathy - Products under Investigation by Universities/Institutes 24
Diabetic Nephropathy - Companies Involved in Therapeutics Development 25
Johnson & Johnson 25
Sanofi 26
Eli Lilly and Company 27
Questcor Pharmaceuticals, Inc. 28
Daiichi Sankyo Company, Limited 29
Emergent BioSolutions Inc. 30
Astellas Pharma Inc. 31
Chong Kun Dang Pharmaceutical Corp. 32
Mitsubishi Tanabe Pharma Corporation 33
Pfizer Inc. 34
NephroGenex, Inc. 35
Bayer AG 36
Gentium S.p.A. 37
Mesoblast Limited 38
Torrent Pharmaceuticals Limited 39
Dongwha Pharm Co., Ltd. 40
PhytoHealth Corporation 41
Angelini Group 42
Cyano Biotech GmbH 43
IMMD Inc. 44
GenKyoTex S.A. 45
Thrasos, Inc. 46
Concert Pharmaceuticals, Inc. 47
Noxxon Pharma AG 48
Intercept Pharmaceuticals, Inc. 49
ChemoCentryx, Inc. 50
Glucox Biotech AB 51
GNI Group Ltd. 52
OncoImmune, Inc. 53
Mitsubishi Pharmaceutical Corporation 54
Fibrotech Therapeutics Pty. Ltd. 55
Ampio Pharmaceuticals, Inc. 56
Stealth Peptides Inc. 57
Galectin Therapeutics 58
AbbVie Inc. 59
Inventiva SAS 60
CCRP Therapeutics GmbH 61
Diabetic Nephropathy - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Target 63
Assessment by Mechanism of Action 67
Assessment by Route of Administration 71
Assessment by Molecule Type 73
Drug Profiles 76
canagliflozin - Drug Profile 76
atrasentan hydrochloride - Drug Profile 78
baricitinib - Drug Profile 79
NOX-E-36 - Drug Profile 81
IMD-1041 - Drug Profile 83
CS-3150 - Drug Profile 84
DW-1029M - Drug Profile 85
GKT-137831 - Drug Profile 86
PF-00489791 - Drug Profile 87
CCX-140 - Drug Profile 88
LY-2382770 - Drug Profile 90
bindarit - Drug Profile 91
Colchicine - Drug Profile 93
probucol - Drug Profile 94
PF-04634817 - Drug Profile 95
Pyridoxamine Dihydrochloride - Drug Profile 96
GLY-230 - Drug Profile 98
corticotropin - Drug Profile 100
CTP-499 - Drug Profile 102
MT-3995 - Drug Profile 104
finerenone - Drug Profile 105
cilostazol - Drug Profile 106
PHN-033 - Drug Profile 107
CKD-322 - Drug Profile 108
Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - Drug Profile 109
LY-3016859 - Drug Profile 111
FT-011 - Drug Profile 112
ASP-8232 - Drug Profile 113
pirfenidone - Drug Profile 114
THR-123 - Drug Profile 115
DT-23552 - Drug Profile 116
DMI-5207 - Drug Profile 117
INT-767 - Drug Profile 118
MTP-131 - Drug Profile 120
A-717 - Drug Profile 122
GR-MD-02 - Drug Profile 123
TNFR x TWEAKR - Drug Profile 125
Oligotide - Drug Profile 126
CCX-872 - Drug Profile 127
GKT-136901 - Drug Profile 128
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 130
Stromal Cell Therapy For Diabetic Complications - Drug Profile 131
HPTPbeta mAb - Drug Profile 132
Vascular Endothelial Growth Factor-165B - Drug Profile 133
MG-132 - Drug Profile 134
GW-610742 - Drug Profile 136
TRC-120038 - Drug Profile 137
Therapy For End-Organ Damage - Drug Profile 138
JNJ-39933673 - Drug Profile 139
11R-VIVIT - Drug Profile 140
Silencing RNA-1 for Diabetic Nephropathy - Drug Profile 141
Silencing RNA-2 for Diabetic Nephropathy - Drug Profile 142
Nephrilin - Drug Profile 143
DCB-DN1 - Drug Profile 144
Drug For Diabetic Nephropathy - Drug Profile 145
Small Molecule To Inhibit NOX-4 For Diabetic Nephropathy - Drug Profile 146
Small Molecule For Diabetic Nephropathy - Drug Profile 147
Microginins ACE Inhibitors­ Program - Drug Profile 148
Diabetic Nephropathy - Recent Pipeline Updates 149
Diabetic Nephropathy - Dormant Projects 179
Diabetic Nephropathy - Discontinued Products 180
Diabetic Nephropathy - Product Development Milestones 181
Featured News & Press Releases 181
Appendix 189
Methodology 189
Coverage 189
Secondary Research 189
Primary Research 189
Expert Panel Validation 189
Contact Us 190
Disclaimer 190

List of Tables

Number of Products under Development for Diabetic Nephropathy, H1 2014 14
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2014 29
Diabetic Nephropathy - Pipeline by Sanofi, H1 2014 30
Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H1 2014 31
Diabetic Nephropathy - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014 32
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 33
Diabetic Nephropathy - Pipeline by Emergent BioSolutions Inc., H1 2014 34
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H1 2014 35
Diabetic Nephropathy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 36
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 37
Diabetic Nephropathy - Pipeline by Pfizer Inc., H1 2014 38
Diabetic Nephropathy - Pipeline by NephroGenex, Inc., H1 2014 39
Diabetic Nephropathy - Pipeline by Bayer AG, H1 2014 40
Diabetic Nephropathy - Pipeline by Gentium S.p.A., H1 2014 41
Diabetic Nephropathy - Pipeline by Mesoblast Limited, H1 2014 42
Diabetic Nephropathy - Pipeline by Torrent Pharmaceuticals Limited, H1 2014 43
Diabetic Nephropathy - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 44
Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H1 2014 45
Diabetic Nephropathy - Pipeline by Angelini Group, H1 2014 46
Diabetic Nephropathy - Pipeline by Cyano Biotech GmbH, H1 2014 47
Diabetic Nephropathy - Pipeline by IMMD Inc., H1 2014 48
Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H1 2014 49
Diabetic Nephropathy - Pipeline by Thrasos, Inc., H1 2014 50
Diabetic Nephropathy - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 51
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2014 52
Diabetic Nephropathy - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014 53
Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2014 54
Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H1 2014 55
Diabetic Nephropathy - Pipeline by GNI Group Ltd., H1 2014 56
Diabetic Nephropathy - Pipeline by OncoImmune, Inc., H1 2014 57
Diabetic Nephropathy - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014 58
Diabetic Nephropathy - Pipeline by Fibrotech Therapeutics Pty. Ltd., H1 2014 59
Diabetic Nephropathy - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 60
Diabetic Nephropathy - Pipeline by Stealth Peptides Inc., H1 2014 61
Diabetic Nephropathy - Pipeline by Galectin Therapeutics, H1 2014 62
Diabetic Nephropathy - Pipeline by AbbVie Inc., H1 2014 63
Diabetic Nephropathy - Pipeline by Inventiva SAS, H1 2014 64
Diabetic Nephropathy - Pipeline by CCRP Therapeutics GmbH, H1 2014 65
Assessment by Monotherapy Products, H1 2014 66
Number of Products by Stage and Target, H1 2014 69
Number of Products by Stage and Mechanism of Action, H1 2014 73
Number of Products by Stage and Route of Administration, H1 2014 76
Number of Products by Stage and Molecule Type, H1 2014 79
Diabetic Nephropathy Therapeutics - Recent Pipeline Updates, H1 2014 153
Diabetic Nephropathy - Dormant Projects, H1 2014 183
Diabetic Nephropathy - Discontinued Products, H1 2014 184

List of Figures

Number of Products under Development for Diabetic Nephropathy, H1 2014 14
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Products, H1 2014 24
Assessment by Monotherapy Products, H1 2014 66
Number of Products by Top 10 Target, H1 2014 67
Number of Products by Stage and Top 10 Target, H1 2014 68
Number of Products by Top 10 Mechanism of Action, H1 2014 71
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 72
Number of Products by Top 10 Route of Administration, H1 2014 75
Number of Products by Stage and Top 10 Route of Administration, H1 2014 76
Number of Products by Top 10 Molecule Type, H1 2014 77
Number of Products by Stage and Top 10 Molecule Type, H1 2014 78